<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Diffuse large B cell lymphoma (DLBCL): Suspected first relapse or refractory disease in patients who are medically fit
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Diffuse large B cell lymphoma (DLBCL): Suspected first relapse or refractory disease in patients who are medically fit
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Diffuse large B cell lymphoma (DLBCL): Suspected first relapse or refractory disease in patients who are medically fit
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Arnold S Freedman, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jonathan W Friedberg, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Robert S Negrin, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Ann S LaCasce, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alan G Rosmarin, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Dec 18, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most patients with diffuse large B cell lymphoma (DLBCL) are cured with initial treatment using
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         plus
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">
          doxorubicin
         </a>
         ,
         <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">
          vincristine
         </a>
         , and
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         (R-CHOP) [
         <a href="#rid1">
          1
         </a>
         ]. However, 10 percent of patients do not respond adequately to initial treatment (primary refractory disease), and nearly one-third of patients will later relapse after achieving a complete response. Prognosis and treatment vary according to whether disease was refractory to initial systemic therapy and with the interval from initial treatment until relapse.
        </p>
        <p>
         This topic will discuss evaluation and management of fit patients with primary refractory disease and first relapse of DLBCL.
        </p>
        <p>
         Management of patients with second or later relapse of DLBCL and patients who are not medically fit is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/132087.html" rel="external">
          "Diffuse large B cell lymphoma (DLBCL): Second or later relapse or patients who are medically unfit"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Diagnosis of relapsed or refractory (r/r) DLBCL requires biopsy confirmation in most cases.
        </p>
        <p>
         Initial evaluation and diagnosis of DLBCL are described separately. (See
         <a class="medical medical_review" href="/z/d/html/4703.html" rel="external">
          "Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H731663377">
         <span class="h2">
          Refractory DLBCL
         </span>
         <span class="headingEndMark">
          —
         </span>
         Primary refractory DLBCL is disease that did not respond adequately to initial systemic therapy.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Description
         </strong>
         – Refractory DLBCL refers to disease that did not achieve a complete response (CR) with initial therapy, based on positron emission tomography (PET)/computed tomography (CT)  (
         <a class="graphic graphic_table graphicRef108973" href="/z/d/graphic/108973.html" rel="external">
          table 1
         </a>
         ) according to Lugano criteria  (
         <a class="graphic graphic_table graphicRef97480" href="/z/d/graphic/97480.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical setting
         </strong>
         – Refractory disease should be suspected in a patient with persistent PET activity (ie, PET score 4 or 5) or clinical evidence of persistent or progressive disease, such as B symptoms (unexplained fevers, sweats, or weight loss), incomplete nodal response, or a new site of disease during or soon after initial systemic therapy for DLBCL.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Confirmatory biopsy
         </strong>
         – A repeat biopsy is generally performed to confirm the diagnosis and to exclude a reactive, post-treatment inflammatory response.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A repeat biopsy may not be required if PET/CT revealed clear progression of the size and metabolic activity of a disease site. If a biopsy is not performed for suspected primary refractory disease, the morphology, immunophenotype, and cytogenetic/molecular features of the initial biopsy specimen should be reviewed to ensure that DLBCL was correctly diagnosed. (See
         <a class="medical medical_review" href="/z/d/html/4703.html" rel="external">
          "Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H350150942">
         <span class="h2">
          Relapsed DLBCL
         </span>
         <span class="headingEndMark">
          —
         </span>
         Relapsed DLBCL refers to disease that recurs after a CR was documented by PET/CT.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical setting
         </strong>
         – Relapsed DLBCL should be suspected in a patient with B symptoms, progressive lymphadenopathy, organomegaly, organ dysfunction, development of an extranodal mass, or unexplained cytopenias after achieving a CR.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Most relapses occur in the first two years after completing treatment, but up to one-fifth of cases occur more than five years after treatment [
         <a href="#rid2">
          2,3
         </a>
         ]. Relapse is usually suspected by history or physical examination; only rarely is relapse identified solely on the basis of routine follow-up imaging [
         <a href="#rid4">
          4,5
         </a>
         ]. Clinical manifestations of DLBCL are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4703.html" rel="external">
          "Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma", section on 'Clinical presentation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Confirmatory biopsy
         </strong>
         – A biopsy is required to confirm the diagnosis of relapsed DLBCL, exclude other conditions (eg, other types of lymphoma, carcinoma, sarcoidosis, tuberculosis, fungal infection, Epstein-Barr virus infection), and assess acquisition of new cytogenetic or molecular features.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Selection of a biopsy site, the importance of an adequate specimen, and analysis of the specimen are described separately. (See
         <a class="medical medical_review" href="/z/d/html/4695.html" rel="external">
          "Clinical presentation and initial evaluation of non-Hodgkin lymphoma", section on 'Lymph node and tissue biopsy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4703.html" rel="external">
          "Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3428059761">
         <span class="h1">
          PRETREATMENT EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pretreatment evaluation should assess medical fitness, restage the disease, and determine prognosis.
        </p>
        <p class="headingAnchor" id="H845667113">
         <span class="h2">
          Clinical/laboratory/pathology
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          History and physical examination
         </strong>
         – The presence of B symptoms and lymph node, organ involvement, or other extranodal disease should be documented by history and physical examination. (See
         <a class="medical medical_review" href="/z/d/html/4729.html" rel="external">
          "Initial treatment of advanced stage diffuse large B cell lymphoma", section on 'Pretreatment evaluation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Neurologic abnormalities
         </strong>
         – Patients with neurologic symptoms or abnormalities on neurologic examination should undergo neuroimaging and lumbar puncture, as described separately. (See
         <a class="medical medical_review" href="/z/d/html/4720.html" rel="external">
          "Secondary central nervous system lymphoma: Clinical features and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Lymphomatous involvement of the central nervous system (CNS) influences the choice of salvage chemotherapy, as described below. (See
         <a class="local">
          'Central nervous system involvement'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Laboratory
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Hematology
         </strong>
         – Complete blood count (CBC) with leukocyte differential count.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Chemistries
         </strong>
         – Serum electrolytes, glucose, blood urea nitrogen (BUN) and creatinine, calcium, uric acid, and liver function tests, including lactate dehydrogenase (LDH).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Infectious diseases
         </strong>
         – Testing for human immunodeficiency virus (HIV) and hepatitis B.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical tests
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Cardiac
         </strong>
         – Echocardiogram or radionuclide ventriculogram (RVG) should be performed, if clinically indicated. If the patient will undergo hematopoietic cell transplantation (HCT), assessment of cardiac function is required prior to transplantation.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Pregnancy testing
         </strong>
         – If appropriate.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2124811349">
         <span class="h2">
          Medical fitness
         </span>
         <span class="headingEndMark">
          —
         </span>
         We assess and classify fitness for treatment according to functional status and comorbid conditions.
        </p>
        <p>
         Age is not a measure of fitness, but some institutions limit autologous HCT to patients ≤75 years.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Assessment
         </strong>
         – Assessment of fitness should include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Performance status
         </strong>
         – Eastern Cooperative Oncology Group (ECOG) performance status  (
         <a class="graphic graphic_table graphicRef72901" href="/z/d/graphic/72901.html" rel="external">
          table 3
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Comorbidity score
         </strong>
         – Charlson comorbidity index (CCI) or the HCT-specific comorbidity index scoring systems  (
         <a class="graphic graphic_table graphicRef59272" href="/z/d/graphic/59272.html" rel="external">
          table 4
         </a>
         ) are helpful for assessing fitness in some patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Medical fitness
         </strong>
         – Patients who can tolerate intensive treatments, such as chimeric antigen receptor (CAR)-T cell therapy, intensive salvage chemotherapy, and autologous HCT, generally have
         <strong>
          both
         </strong>
         of the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         ECOG: 0 to 2  (
         <a class="graphic graphic_table graphicRef72901" href="/z/d/graphic/72901.html" rel="external">
          table 3
         </a>
         )
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         CCI: 0 to 2  (
         <a class="graphic graphic_table graphicRef59272" href="/z/d/graphic/59272.html" rel="external">
          table 4
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Transplant eligibility
         </strong>
         – Patients (except frail individuals) should be evaluated for transplantation eligibility soon after the diagnosis of relapsed or refractory (r/r) DLBCL.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Although no specific age excludes autologous HCT, many institutions limit transplantation to patients ≤75 years with adequate heart, kidney, and liver function and performance status, as discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/16354.html" rel="external">
          "Determining eligibility for autologous hematopoietic cell transplantation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Geriatric assessment may be useful for judging medical fitness of some patients in this setting [
         <a href="#rid6">
          6
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4530.html" rel="external">
          "Acute myeloid leukemia: Management of medically unfit adults", section on 'Pretreatment evaluation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4008532947">
         <span class="h2">
          Restaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         Restaging is based on clinical evaluation, laboratory studies, and positron emission tomography (PET)/CT, according to the Lugano criteria  (
         <a class="graphic graphic_table graphicRef97479" href="/z/d/graphic/97479.html" rel="external">
          table 5
         </a>
         ). Disease stage at relapse should be designated by subscript R (
         <sub>
          R
         </sub>
         ).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Imaging
         </strong>
         – PET/CT is scored using the five-point (Deauville) scale  (
         <a class="graphic graphic_table graphicRef108973" href="/z/d/graphic/108973.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bone marrow examination
         </strong>
         – Bone marrow aspirate and biopsy are generally not required for restaging r/r DLBCL because PET is a good predictor for marrow involvement.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         However, bone marrow examination may be useful in patients with cytopenias (especially in older patients) who may later undergo HCT or CAR-T cell therapy, as they may experience prolonged postprocedure cytopenias. The choice of CAR-T cell therapy versus autologous HCT may be influenced by detection of marrow "packed" with lymphoma, myelodysplasia, or profound hypoplasia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If bone marrow examination
         <strong>
         </strong>
         is performed, it should be analyzed by microscopy, cytogenetics (using fluorescence in situ hybridization or Giemsa-stained chromosomes), and molecular studies, as described separately. (See
         <a class="medical medical_review" href="/z/d/html/4703.html" rel="external">
          "Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2253007206">
         <span class="h2">
          Prognosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         We apply the International Prognostic Index (IPI)  (
         <a class="graphic graphic_table graphicRef70850" href="/z/d/graphic/70850.html" rel="external">
          table 6
         </a>
         ) at the time of diagnosis of r/r DLBCL. The IPI has been validated as a prognostic tool in this setting [
         <a href="#rid7">
          7,8
         </a>
         ].
        </p>
        <p>
         In the CORAL trial, event-free survival (EFS) at three years was lower in patients with age-adjusted IPI score 2 to 3 compared with patients with IPI score 0 to 1 (18 versus 40 percent, respectively) [
         <a href="#rid9">
          9
         </a>
         ]. The prognostic value of the IPI score for relapsed disease was also validated in the Parma trial [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
         Other factors that have been associated with outcomes in r/r DLBCL include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Duration of remission
         </strong>
         – Longer duration of initial complete response is generally associated with a more favorable response to salvage chemotherapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients who relapsed &lt;12 versus &gt;12 months after initial diagnosis in the Parma trial, which was conducted prior to the
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         era, overall response rates to salvage chemotherapy were 40 and 69 percent, respectively; it is uncertain if such differences would be seen in the rituximab era [
         <a href="#rid11">
          11
         </a>
         ]. In a retrospective analysis of 162 patients with relapsed DLBCL, overall survival (OS) did not differ between those whose initial duration of remission was ≥5 versus &lt;5 years [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pathologic features
         </strong>
         – In the CORAL trial, compared with patients whose tumors did not have
         <em>
          MYC
         </em>
         rearrangement, those with a
         <em>
          MYC
         </em>
         rearrangement had inferior rates of four-year progression-free survival (18 versus 42 percent, respectively) and four-year OS (29 versus 62 percent, respectively) [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2993508654">
         <span class="h1">
          OVERVIEW OF MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The preferred approach for medically fit patients varies with the clinical setting  (
         <a class="graphic graphic_algorithm graphicRef142186" href="/z/d/graphic/142186.html" rel="external">
          algorithm 1
         </a>
         ), as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Early relapse
         </strong>
         – Relapse &lt;12 months after completing initial therapy or primary refractory DLBCL (see
         <a class="local">
          'Relapse &lt;12 months or primary refractory DLBCL'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Later relapse
         </strong>
         – Relapse ≥12 months after initial therapy (see
         <a class="local">
          'Relapse ≥12 months after treatment'
         </a>
         below)
        </p>
        <p>
        </p>
        <p>
         For patients with documented central nervous system (CNS) involvement, CNS disease should be controlled before or at the time when systemic therapy begins. Management of CNS involvement by DLBCL is described separately. (See
         <a class="medical medical_review" href="/z/d/html/89417.html" rel="external">
          "Secondary central nervous system lymphoma: Treatment and prognosis", section on 'Diffuse large B cell lymphoma'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3334776372">
         <span class="h1">
          RELAPSE &lt;12 MONTHS OR PRIMARY REFRACTORY DLBCL
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with early first relapse (&lt;12 months) or primary refractory DLBCL, we recommend CD19-directed chimeric antigen receptor (CAR)-T cell therapy using
         <a class="drug drug_general" data-topicid="115350" href="/z/d/drug information/115350.html" rel="external">
          axicabtagene ciloleucel
         </a>
         or
         <a class="drug drug_general" data-topicid="130728" href="/z/d/drug information/130728.html" rel="external">
          lisocabtagene maraleucel
         </a>
         , rather than autologous hematopoietic cell transplantation (HCT) or
         <a class="drug drug_general" data-topicid="114674" href="/z/d/drug information/114674.html" rel="external">
          tisagenlecleucel
         </a>
         (
         <a class="graphic graphic_algorithm graphicRef142186" href="/z/d/graphic/142186.html" rel="external">
          algorithm 1
         </a>
         ). This recommendation is based on superior survival using axicabtagene ciloleucel or lisocabtagene maraleucel compared with autologous HCT in randomized trials [
         <a href="#rid14">
          14,15
         </a>
         ]; tisagenlecleucel did not achieve better outcomes than autologous HCT in a separate randomized trial [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Administration
         </strong>
         – CAR-T cell therapy is a form of immunotherapy in which the patient's own T lymphocytes are transfected ex vivo with a gene that encodes a CAR to direct the patient's immune system against the lymphoma. Manufacturing is complex and expensive, administration is limited to qualified institutions, and the preferred product varies among institutions. Treatment with CD19-directed CAR-T cell therapy is discussed below. (See
         <a class="local">
          'CD19-directed chimeric antigen receptor-T cell therapy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bridging therapy prior to chimeric antigen receptor-T cell infusion
         </strong>
         – Treatment may be required to control progressive disease after T cell collection but prior to CAR-T infusion.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We generally avoid using CD19-directed treatments (eg,
         <a class="drug drug_general" data-topicid="129156" href="/z/d/drug information/129156.html" rel="external">
          tafasitamab
         </a>
         , loncastuximab) as bridging therapy prior to CD19-directed CAR-T cell therapy. Options for bridging therapy include polatuzumab, chemotherapy, radiation therapy, and other approaches, as discussed separately.
         <strong>
         </strong>
         (See
         <a class="medical medical_review" href="/z/d/html/132087.html" rel="external">
          "Diffuse large B cell lymphoma (DLBCL): Second or later relapse or patients who are medically unfit", section on 'Treatments'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Toxicity
         </strong>
         – All CAR-T cell products are associated with potentially fatal complications, but the spectrum and severity of adverse effects (AEs) may vary among the individual products. At present, it appears that
         <a class="drug drug_general" data-topicid="130728" href="/z/d/drug information/130728.html" rel="external">
          lisocabtagene maraleucel
         </a>
         is associated with less toxicity than the other commercially available CAR-T cell products.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The most severe complications of CAR-T cell therapy are:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Cytokine release syndrome
         </strong>
         – A severe systemic response to the activation and proliferation of CAR-T cells typically manifests as high fever, flu-like symptoms, hypotension, and mental status changes. Some degree of cytokine release syndrome (CRS) is observed in nearly all treated patients and may be life threatening for some, but it typically responds to treatment with aggressive supportive care that includes
         <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">
          tocilizumab
         </a>
         and corticosteroids, as described separately. (See
         <a class="medical medical_review" href="/z/d/html/118012.html" rel="external">
          "Cytokine release syndrome (CRS)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Immune effector cell-associated neurotoxicity syndrome
         </strong>
         – This neurotoxicity can be severe or life threatening, as described separately. (See
         <a class="medical medical_review" href="/z/d/html/129618.html" rel="external">
          "Immune effector cell-associated neurotoxicity syndrome (ICANS)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          T cell lymphomas
         </strong>
         – Reports are emerging of T cell malignancies in patients who received CD19- or BCMA (B cell maturation antigen)-directed CAR-T cell therapy; malignant cells in some of these lymphomas are CAR positive [
         <a href="#rid17">
          17
         </a>
         ]. Although rare, the actual incidence of secondary T cell lymphomas is not well defined, and it is uncertain if these tumors are associated with all CAR-T cell products.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         The potential risk of secondary malignancies is a class warning in prescribing information for all US Food and Drug Administration (FDA)-approved CD19- and BCMA-directed autologous T cell immunotherapies. At present, no products have been recalled, and no regulatory action has been taken.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         If a new malignancy occurs following CAR-T cell therapy, the event should be reported to the manufacturer and to the FDA AE Reporting System (FAERS) [
         <a href="#rid18">
          18
         </a>
         ]. Patients receiving any CAR-T cell product should be monitored life-long for development of new malignancies.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Chimeric antigen receptor-T cell therapy versus autologous hematopoietic cell transplantation for early relapse or refractory DLBCL
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Axicabtagene ciloleucel
         </strong>
         –
         <a class="drug drug_general" data-topicid="115350" href="/z/d/drug information/115350.html" rel="external">
          Axicabtagene ciloleucel
         </a>
         comprises a murine anti-CD19 single chain variable fragment (scFv) linked to CD28 and CD3 zeta costimulatory domains. Axicabtagene ciloleucel is approved by the FDA for adults with primary refractory DLBCL, relapse &lt;12 months, and relapsed or refractory (r/r) DLBCL after ≥2 lines of systemic therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         In the phase 3 ZUMA-7 trial,
         <a class="drug drug_general" data-topicid="115350" href="/z/d/drug information/115350.html" rel="external">
          axicabtagene ciloleucel
         </a>
         achieved superior outcomes in 359 patients with r/r DLBCL who were randomly assigned to axicabtagene ciloleucel versus standard care (salvage chemotherapy followed by autologous HCT) [
         <a href="#rid19">
          19
         </a>
         ]. High-risk features were common; three-quarters of patients had primary refractory DLBCL, nearly one-third were ≥65 years, and one-fifth had adverse pathologic features. With a median follow-up of 47 months, axicabtagene ciloleucel achieved superior, four-year overall survival (OS; 55 versus 46 percent; hazard ratio [HR] 0.73 [95% CI 0.54-0.98]) and progression-free survival (PFS; 42 versus 24 percent; HR 0.51 [95% CI 0.38-0.67]). Grade ≥3 CRS was reported in 6 percent of patients and grade ≥3 neurologic events in 21 percent; there were no deaths attributed to CRS or neurologic events [
         <a href="#rid14">
          14
         </a>
         ]. In a separate report, axicabtagene ciloleucel was associated with improved quality of life compared with standard care, including patients ≥65 years [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Lisocabtagene maraleucel
         </strong>
         –
         <a class="drug drug_general" data-topicid="130728" href="/z/d/drug information/130728.html" rel="external">
          Lisocabtagene maraleucel
         </a>
         is an anti-CD19 CAR-T cell product with a 4-1BB (CD137) costimulatory domain that is administered as sequential infusions of two components (CD8-positive and CD4-positive CAR-T cells, which are selected from the leukapheresis material and independently activated, transduced, and expanded) [
         <a href="#rid21">
          21
         </a>
         ]. Lisocabtagene maraleucel is approved by the FDA for primary refractory DLBCL or relapse &lt;12 months after first-line systemic therapy in patients who are not eligible for HCT and for r/r DLBCL after ≥2 lines of systemic therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <a class="drug drug_general" data-topicid="130728" href="/z/d/drug information/130728.html" rel="external">
          Lisocabtagene maraleucel
         </a>
         achieved better outcomes than autologous HCT according to interim analysis of the phase 3 TRANSFORM trial [
         <a href="#rid15">
          15
         </a>
         ]. With a median follow-up of six months, lisocabtagene maraleucel achieved superior median OS (not reached versus 16 months [95% CI 0.26-1]), event-free survival (EFS; 10 versus 2 months; HR 0.35 [95% CI 0.23-0.53]), PFS (14 versus 6 months; HR 0.41 [95% CI 0.25-0.66]), overall response rate (ORR; 79 versus 48 percent), complete response (CR; 61 versus 36 percent), and had an acceptable safety profile among 184 patients with early relapse or primary refractory DLBCL [
         <a href="#rid15">
          15
         </a>
         ]. In another study, lisocabtagene maraleucel was associated with improved, patient-reported quality of life, cognitive function, fatigue, and pain compared with standard care [
         <a href="#rid22">
          22
         </a>
         ]. In the multicenter TRANSCEND NHL001 study, lisocabtagene maraleucel was associated with a 73 percent ORR, 53 percent CR, 17-month median duration of response (DOR), and 55 percent one-year DOR among 256 evaluable patients with r/r DLBCL [
         <a href="#rid21">
          21
         </a>
         ]. Grade ≥3 CRS was reported in 2 percent and grade ≥3 neurologic events in 10 percent of treated patients; 3 percent of patients died with treatment-associated AEs.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Tisagenlecleucel
         </strong>
         –
         <a class="drug drug_general" data-topicid="114674" href="/z/d/drug information/114674.html" rel="external">
          Tisagenlecleucel
         </a>
         comprises a murine anti-CD19 scFv linked to a CD8 hinge and a transmembrane region fused to intracellular signaling domains for 4-1BB and CD3 zeta [
         <a href="#rid23">
          23
         </a>
         ]. Tisagenlecleucel is approved by the FDA after ≥2 lines of systemic therapy for adults with r/r DLBCL, high-grade B cell lymphoma, and DLBCL arising from follicular lymphoma.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         In a phase 3 trial of
         <a class="drug drug_general" data-topicid="114674" href="/z/d/drug information/114674.html" rel="external">
          tisagenlecleucel
         </a>
         versus autologous HCT, the median EFS was three months for both groups, and the ORR was similar (46 percent for tisagenlecleucel versus 43 percent for standard care) among 322 patients with early relapse or primary refractory DLBCL [
         <a href="#rid16">
          16
         </a>
         ]. Deaths from treatment-related AEs were reported in 10 of 161 patients treated with tisagenlecleucel.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1180624000">
         <span class="h1">
          RELAPSE ≥12 MONTHS AFTER TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with a late first relapse of DLBCL (eg, ≥12 months after completing therapy), we suggest salvage chemotherapy followed by autologous hematopoietic cell transplantation (HCT) rather than salvage chemotherapy alone or chimeric antigen receptor (CAR)-T cell therapy  (
         <a class="graphic graphic_algorithm graphicRef142186" href="/z/d/graphic/142186.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p>
         Autologous HCT following a complete response (CR) or near-CR after salvage chemotherapy has long been standard care for transplant-eligible patients. No randomized trials have directly compared autologous HCT with CAR-T cell therapy for late relapse of DLBCL, but autologous transplantation is associated with long-term survival in at least one-half of patients with first relapse of DLBCL and better survival than salvage chemotherapy alone.
        </p>
        <p>
         Autologous HCT involves the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Intensive salvage chemotherapy
         </strong>
         – Two or three cycles of intensive salvage therapy are given to reduce the burden of disease and determine if the relapsed DLBCL is sensitive to chemotherapy based on positron emission tomography (PET)/CT. Choice of a salvage chemotherapy regimen is discussed below. (See
         <a class="local">
          'Selection of salvage chemotherapy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Response to salvage chemotherapy
         </strong>
         – Subsequent care is guided by PET/CT response  (
         <a class="graphic graphic_algorithm graphicRef142186" href="/z/d/graphic/142186.html" rel="external">
          algorithm 1
         </a>
         ), using the five-point scale (Deauville score)  (
         <a class="graphic graphic_table graphicRef108973" href="/z/d/graphic/108973.html" rel="external">
          table 1
         </a>
         ), according to Lugano criteria  (
         <a class="graphic graphic_table graphicRef97480" href="/z/d/graphic/97480.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Response to salvage therapy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Autologous hematopoietic cell transplantation
         </strong>
         – Graft source and conditioning regimen are discussed below. (See
         <a class="local">
          'Autologous hematopoietic cell transplantation'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         In the phase 3 Parma trial, autologous HCT achieved superior overall survival (OS) compared with salvage therapy alone [
         <a href="#rid24">
          24
         </a>
         ]. Among 109 patients with chemotherapy-sensitive lymphoma (most of whom had DLBCL), patients randomly assigned to transplantation had a superior OS (53 versus 32 percent), overall response rate (ORR; 84 versus 44 percent), and event-free survival (EFS; 46 versus 12 percent), compared with four additional cycles of R-DHAP chemotherapy (
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         ,
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         , high-dose
         <a class="drug drug_general" data-topicid="9314" href="/z/d/drug information/9314.html" rel="external">
          cytarabine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         ). However, transplantation was more toxic than chemotherapy; 4 of 49 patients died with transplant-related effects (three infections, one cardiac toxicity), while none of the chemotherapy-only patients died from treatment. However, this trial was performed prior to the use of mobilized peripheral blood stem and progenitor cells (PBSPCs) as a stem cell source; contemporary approaches, which also feature improved supportive care, are associated with lower risk of mortality (eg, 1 to 2 percent) [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p>
         Outcomes with autologous HCT from phase 3 trials of CAR-T cell therapy versus transplantation for primary refractory DLBCL and early relapse are discussed above. (See
         <a class="local">
          'Relapse &lt;12 months or primary refractory DLBCL'
         </a>
         above.)
        </p>
        <p>
         Our approach to autologous HCT for relapsed DLBCL is consistent with guidelines of the United States National Comprehensive Cancer Network [
         <a href="#rid26">
          26
         </a>
         ], the European Society of Medical Oncology [
         <a href="#rid27">
          27
         </a>
         ], and the American Society for Blood and Marrow Transplantation [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3329390180">
         <span class="h1">
          TREATMENTS
         </span>
        </p>
        <p class="headingAnchor" id="H3250222334">
         <span class="h2">
          CD19-directed chimeric antigen receptor-T cell therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chimeric antigen receptor (CAR)-T cell therapy is a form of immunotherapy that directs the patient’s own T lymphocytes against the lymphoma. The manufacturing process is complex and expensive, administration is limited to qualified institutions, and the preferred product differs among institutions. CAR-T cell therapy can cause potentially fatal cytokine release syndrome (CRS) and neurologic toxicity.
        </p>
        <p>
         Three commercially available, anti-CD19 CAR-T cell products are currently available:
         <a class="drug drug_general" data-topicid="115350" href="/z/d/drug information/115350.html" rel="external">
          axicabtagene ciloleucel
         </a>
         ,
         <a class="drug drug_general" data-topicid="130728" href="/z/d/drug information/130728.html" rel="external">
          lisocabtagene maraleucel
         </a>
         , and
         <a class="drug drug_general" data-topicid="114674" href="/z/d/drug information/114674.html" rel="external">
          tisagenlecleucel
         </a>
         .
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Manufacture
         </strong>
         – CAR-T cells are generated from the patient's own T lymphocytes, which are genetically modified (transfected) ex vivo with a gene that encodes a CAR to direct the patient's immune system against the lymphoma. The T cells are expanded in a production facility and then infused back into the patient as therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Products
         </strong>
         – Commercially available, CD19-directed CAR-T cell products differ modestly in molecular design, but they also differ regarding manufacturing time, preferred bridging therapy, and adverse effects (AEs) [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Toxicity
         </strong>
         – All CAR-T cell products are associated with serious and potentially fatal complications, but the rates and spectrum of AEs vary with the individual products. Presently, it appears that
         <a class="drug drug_general" data-topicid="130728" href="/z/d/drug information/130728.html" rel="external">
          lisocabtagene maraleucel
         </a>
         is associated with less toxicity than the other products.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The most severe complications of treatment include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Cytokine release syndrome
         </strong>
         – A severe systemic response to the activation and proliferation of CAR-T cells that typically manifests as high fever, flu-like symptoms, hypotension, and mental status changes. Some degree of CRS is observed in nearly all treated patients and may be life threatening for some, but it typically responds to treatment with aggressive supportive care that includes
         <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">
          tocilizumab
         </a>
         and corticosteroids, as described separately. (See
         <a class="medical medical_review" href="/z/d/html/118012.html" rel="external">
          "Cytokine release syndrome (CRS)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Immune effector cell-associated neurotoxicity syndrome
         </strong>
         – This neurotoxicity can be severe or life threatening, as described separately. (See
         <a class="medical medical_review" href="/z/d/html/129618.html" rel="external">
          "Immune effector cell-associated neurotoxicity syndrome (ICANS)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Other adverse effects
         </strong>
         – Other AEs include hypersensitivity reactions; serious infections; prolonged cytopenias; prolonged hypogammaglobulinemia; and second malignancies, including treatment-related myeloid neoplasms (eg, myelodysplastic syndrome [MDS] or acute myeloid leukemia [AML]).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mitigation strategy
         </strong>
         – The US Food and Drug Administration (FDA) labels carry a boxed warning for CRS and neurologic events. In the United States, CAR-T cell products are only available through a risk evaluation and mitigation strategy (REMS). Facilities that dispense these agents require special certification, staff must be trained to recognize and manage AEs, and
         <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">
          tocilizumab
         </a>
         (a humanized monoclonal antibody against the interleukin 6 receptor) must be available for immediate administration.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4101807567">
         <span class="h2">
          Autologous transplantation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Autologous hematopoietic cell transplantation (HCT) is generally reserved for medically fit patients with late first relapse of DLBCL who achieve a complete response (CR) or near-CR with salvage chemotherapy, as discussed above. (See
         <a class="local">
          'Relapse ≥12 months after treatment'
         </a>
         above.)
        </p>
        <p>
         Note that in treating relapsed or refractory (r/r) DLBCL, we distinguish between:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Salvage therapy
         </strong>
         – Intensive treatment that reduces the burden of disease while determining if it is sensitive to chemotherapy (and thus amenable to transplantation).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Conditioning therapy
         </strong>
         – High-dose chemotherapy (and occasionally immunotherapy or radiation therapy) administered immediately prior to HCT.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H16594424">
         <span class="h3">
          Selection of salvage chemotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with r/r DLBCL who are candidates for autologous HCT, we suggest intensive salvage therapy rather than lower-intensity therapy because intensive treatment is more likely to achieve a robust response that enables transplantation [
         <a href="#rid9">
          9,30-32
         </a>
         ]. No studies have directly compared intensive salvage regimens with lower-intensity regimens, and comparisons across studies are difficult because of different inclusion criteria, pathologic features, patient composition, and outcome measures.
        </p>
        <p>
         Salvage regimens are presented below. (See
         <a class="local">
          'Salvage regimens'
         </a>
         below.)
        </p>
        <p>
         Prophylaxis for tumor lysis syndrome (TLS) should be considered for patients who have a high tumor burden (eg, large tumor masses or markedly elevated lactate dehydrogenase [LDH]). Prophylaxis for TLS is described separately. (See
         <a class="medical medical_review" href="/z/d/html/17050.html" rel="external">
          "Tumor lysis syndrome: Prevention and treatment"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Central nervous system
         </strong>
         <strong>
          involvement or higher risk for central nervous system
         </strong>
         <strong>
          involvement
         </strong>
         – We stratify selection of a salvage regimen according to the presence or higher risk for central nervous system (CNS) involvement. There is no consensus, but for patients who presented with DLBCL, features associated with higher risk for CNS involvement include ≥2 of the following (see
         <a class="medical medical_review" href="/z/d/html/4729.html" rel="external">
          "Initial treatment of advanced stage diffuse large B cell lymphoma", section on 'Central nervous system (CNS) evaluation'
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Age &gt;60 years
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Elevated LDH
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Eastern Cooperative Oncology Group (ECOG) performance status &gt;1
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Extranodal involvement at &gt;1 site
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Kidney or adrenal involvement
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Salvage therapy for patients with CNS involvement or higher risk for CNS involvement is discussed below. (See
         <a class="local">
          'Central nervous system involvement'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          No central nervous system involvement
         </strong>
         – For patients who do
         <strong>
          not
         </strong>
         have CNS involvement or higher risk for CNS involvement, selection of a salvage regimen is discussed below. (See
         <a class="local">
          'No central nervous system involvement'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1254935954">
         <span class="h4">
          No central nervous system involvement
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with no CNS involvement or higher-risk features for CNS disease, we select an intensive salvage regimen based on comorbidities, toxicity, pathologic features, clinician experience, and convenience (ie, outpatient administration). Higher risk for CNS involvement is discussed above. (See
         <a class="local">
          'Selection of salvage chemotherapy'
         </a>
         above.)
        </p>
        <p>
         The following regimens have similar efficacy and potential for proceeding to HCT, but AEs and the preferred regimen vary among institutions:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          R-GDP (
         </strong>
         <strong>
          rituximab
         </strong>
         <strong>
          ,
         </strong>
         <strong>
          gemcitabine
         </strong>
         <strong>
          ,
         </strong>
         <strong>
          dexamethasone
         </strong>
         <strong>
          ,
         </strong>
         <strong>
          cisplatin
         </strong>
         <strong>
          )
         </strong>
         – (See
         <a class="local">
          'R-GDP (rituximab, gemcitabine, dexamethasone, cisplatin)'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          R-ICE
         </strong>
         <strong>
          (
         </strong>
         <strong>
          rituximab
         </strong>
         <strong>
          ,
         </strong>
         <strong>
          ifosfamide
         </strong>
         <strong>
          ,
         </strong>
         <strong>
          carboplatin
         </strong>
         <strong>
          ,
         </strong>
         <strong>
          etoposide
         </strong>
         <strong>
          )
         </strong>
         – (See
         <a class="local">
          'R-ICE (rituximab, ifosfamide, carboplatin, etoposide)'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          R-DHAP (
         </strong>
         <strong>
          rituximab
         </strong>
         <strong>
          ,
         </strong>
         <strong>
          dexamethasone
         </strong>
         <strong>
          , high-dose
         </strong>
         <strong>
          cytarabine
         </strong>
         <strong>
          , plus a platin)
         </strong>
         – (See
         <a class="local">
          'R-DHAP (rituximab, dexamethasone, high-dose cytarabine, plus a platin)'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          R-GemOx (
         </strong>
         <strong>
          rituximab
         </strong>
         <strong>
          ,
         </strong>
         <strong>
          gemcitabine
         </strong>
         <strong>
          ,
         </strong>
         <strong>
          oxaliplatin
         </strong>
         <strong>
          )
         </strong>
         – (See
         <a class="local">
          'R-GemOx (rituximab, gemcitabine, oxaliplatin)'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         Factors that may influence the choice of a salvage regimen are:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Outpatient administration
         </strong>
         – R-GDP and R-ICE can be administered in the outpatient setting.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prior
         </strong>
         <strong>
          etoposide
         </strong>
         <strong>
          therapy
         </strong>
         – We generally avoid R-ICE for patients who previously received R-EPOCH (
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         ,
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          etoposide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         ,
         <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">
          vincristine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">
          doxorubicin
         </a>
         ) or other etoposide-containing regimens.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Kidney function
         </strong>
         – For patients with limited kidney function, carboplatin-based salvage therapy may be preferred over cisplatin-based therapy. Some experts treat with
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         , although it is not FDA approved in this setting.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3863069194">
         <span class="h4">
          Central nervous system involvement
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with documented CNS involvement and for selected patients at higher risk for CNS involvement, we suggest a high-dose cytarabine-based salvage regimen, rather than other regimens. No studies have directly compared high-dose cytarabine-based salvage therapy with other regimens for r/r DLBCL; this suggestion is based on activity of such regimens against primary and secondary CNS lymphoma. (See
         <a class="medical medical_review" href="/z/d/html/89417.html" rel="external">
          "Secondary central nervous system lymphoma: Treatment and prognosis", section on 'Relapsed DLBCL, secondary CNS disease'
         </a>
         .)
        </p>
        <p>
         Higher risk for CNS involvement is described above. (See
         <a class="local">
          'Selection of salvage chemotherapy'
         </a>
         above.)
        </p>
        <p>
         High-dose cytarabine-based salvage regimens include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          R-DHAP (
         </strong>
         <strong>
          rituximab
         </strong>
         <strong>
          ,
         </strong>
         <strong>
          dexamethasone
         </strong>
         <strong>
          , high-dose
         </strong>
         <strong>
          cytarabine
         </strong>
         <strong>
          , plus a platin)
         </strong>
         – (See
         <a class="local">
          'R-DHAP (rituximab, dexamethasone, high-dose cytarabine, plus a platin)'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          R-ESHAP (
         </strong>
         <strong>
          rituximab
         </strong>
         <strong>
          ,
         </strong>
         <strong>
          etoposide
         </strong>
         <strong>
          ,
         </strong>
         <strong>
          methylprednisolone
         </strong>
         <strong>
          ,
         </strong>
         <strong>
          cytarabine
         </strong>
         <strong>
          ,
         </strong>
         <strong>
          cisplatin
         </strong>
         <strong>
          )
         </strong>
         – (See
         <a class="local">
          'R-ESHAP (rituximab, etoposide, methylprednisolone, cytarabine, cisplatin)'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         Some experts consider methotrexate-containing regimens (eg, MATRix-RICE) acceptable based on treatment of patients with secondary CNS lymphoma involvement. (See
         <a class="medical medical_review" href="/z/d/html/89417.html" rel="external">
          "Secondary central nervous system lymphoma: Treatment and prognosis", section on 'Relapsed DLBCL, secondary CNS disease'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2715376419">
         <span class="h3">
          Salvage regimens
         </span>
         <span class="headingEndMark">
          —
         </span>
         Common intensive salvage regimens for r/r DLBCL follow.
        </p>
        <p class="headingAnchor" id="H1479427602">
         <span class="h4">
          R-GDP (rituximab, gemcitabine, dexamethasone, cisplatin)
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Administration
         </strong>
         – R-GDP includes
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         375 mg/m
         <sup>
          2
         </sup>
         intravenously on day -1,
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         1000 mg/m
         <sup>
          2
         </sup>
         per day on days 1 and 8,
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         40 mg by mouth daily on days 1 through 4, and
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         75 mg/m
         <sup>
          2
         </sup>
         on day 1, administered at 21-day intervals [
         <a href="#rid30">
          30,33,34
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects
         </strong>
         – Hematologic toxicity is universal, and febrile neutropenia is seen in approximately 15 percent of patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Outcomes
         </strong>
         – R-GDP was less toxic but had comparable efficacy compared with R-DHAP in the phase 3 LY.12 trial [
         <a href="#rid30">
          30
         </a>
         ]. R-GDP has not been compared head-to-head with other salvage regimens.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In the LY.12 trial, 619 patients (69 percent had r/r DLBCL) were randomly assigned to R-GDP versus R-DHAP [
         <a href="#rid30">
          30
         </a>
         ]. There was no difference in the overall survival (OS), event-free survival (EFS), overall response rate (ORR; 45 versus 44 percent), or ability to proceed to autologous HCT (52 versus 49 percent), but R-GDP was associated with fewer episodes of grade ≥3 toxicity (47 versus 61 percent), less hospitalization (47 versus 99 percent), and better, patient-reported quality of life. There were eight treatment-related deaths (two patients receiving R-GDP, six with R-DHAP).
         <strong>
         </strong>
         However, some experts favor R-DHAP in patients with germinal center B cell (GCB) features based on a retrospective study [
         <a href="#rid35">
          35
         </a>
         ], as described below. (See
         <a class="local">
          'R-DHAP (rituximab, dexamethasone, high-dose cytarabine, plus a platin)'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H639239741">
         <span class="h4">
          R-ICE (rituximab, ifosfamide, carboplatin, etoposide)
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Administration
         </strong>
         – R-ICE includes
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         375 mg/m
         <sup>
          2
         </sup>
         on day -1;
         <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">
          ifosfamide
         </a>
         5000 mg/m
         <sup>
          2
         </sup>
         continuous infusion for 24 hours on day 2;
         <a class="drug drug_general" data-topicid="9615" href="/z/d/drug information/9615.html" rel="external">
          mesna
         </a>
         100 mg/m
         <sup>
          2
         </sup>
         on days 1, 2, and 3;
         <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">
          carboplatin
         </a>
         (area under the curve 5 [maximum dose 800 mg] on day 2); and
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          etoposide
         </a>
         100 mg/m
         <sup>
          2
         </sup>
         per day on days 1, 2, and 3  (
         <a class="graphic graphic_table graphicRef76030" href="/z/d/graphic/76030.html" rel="external">
          table 7
         </a>
         ) and is generally given every 21 days [
         <a href="#rid9">
          9,36,37
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects
         </strong>
         – Hematologic toxicity is universal, with one-third of patients requiring transfusions, and grade ≥3 nonhematologic AEs include infection (in up to one-quarter of patients) and occasional nephrotoxicity.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Outcomes
         </strong>
         – In the phase 3 CORAL trial, there was no difference in outcomes among 396 patients who were randomly assigned to three cycles of salvage therapy using R-ICE versus three cycles of R-DHAP, but R-DHAP caused more kidney toxicity [
         <a href="#rid9">
          9
         </a>
         ]. R-DHAP and R-ICE achieved comparable ORR (64 versus 63 percent), three-year EFS (26 and 35 percent), and three-year OS (47 and 51 percent). In both arms, 16 percent of patients had febrile neutropenia, but R-DHAP was associated with grade 4 renal toxicity in 11 patients, and more patients needed platelet transfusions (57 versus 35 percent).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1297028183">
         <span class="h4">
          R-GemOx (rituximab, gemcitabine, oxaliplatin)
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Administration
         </strong>
         – R-GemOx includes
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         375 mg/m
         <sup>
          2
         </sup>
         on day -1,
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         1000 mg/m
         <sup>
          2
         </sup>
         on day 2, and
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         100 mg/m
         <sup>
          2
         </sup>
         on day 2 [
         <a href="#rid38">
          38,39
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects
         </strong>
         – Severe hematologic toxicity occurs in one-half of patients, and neuropathy can occur.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Outcomes
         </strong>
         – R-GemOx is associated with ORR in up to one-half of patients and complete response (CR) in up to one-third of patients with r/r DLBCL [
         <a href="#rid31">
          31,38-41
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          Oxaliplatin
         </a>
         has not been approved by the FDA for treatment of r/r DLBCL.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4238420038">
         <span class="h4">
          R-DHAP (rituximab, dexamethasone, high-dose cytarabine, plus a platin)
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Administration
         </strong>
         – R-DHAP includes
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         375 mg/m
         <sup>
          2
         </sup>
         on day -1,
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         40 mg/day on days 1 to 4,
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         100 mg/m
         <sup>
          2
         </sup>
         on day 1 by continuous infusion, and
         <a class="drug drug_general" data-topicid="9314" href="/z/d/drug information/9314.html" rel="external">
          cytarabine
         </a>
         2 g/m
         <sup>
          2
         </sup>
         in a three-hour infusion on day 2 every three weeks [
         <a href="#rid9">
          9
         </a>
         ]. Some experts use
         <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">
          carboplatin
         </a>
         [
         <a href="#rid42">
          42
         </a>
         ] or
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         [
         <a href="#rid43">
          43
         </a>
         ] to avoid the nephrotoxicity of cisplatin.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients with pre-existent kidney insufficiency, some experts replace
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         with
         <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">
          carboplatin
         </a>
         or
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         to lessen nephrotoxicity, but there are limited outcomes data with these regimens [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects
         </strong>
         – Hematologic toxicity is universal, with one-third of patients requiring transfusions, and grade ≥3 nonhematologic AEs include infection (in up to one-quarter of patients) and occasional nephrotoxicity.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Outcomes
         </strong>
         – In the phase 3 CORAL trial, outcomes were similar among 396 patients who were randomly assigned to three cycles of salvage therapy using R-DHAP versus R-ICE, but R-DHAP caused more kidney toxicity [
         <a href="#rid9">
          9
         </a>
         ]. The two trial arms achieved a comparable ORR (64 versus 63 percent), three-year EFS (26 and 35 percent), and three-year OS (47 and 51 percent). In both arms, 16 percent of the patients had febrile neutropenia, but R-DHAP was associated with grade 4 renal toxicity in 11 patients, and more patients needed platelet transfusions (57 versus 35 percent). The LY.12 and ORCHARRD phase 3 trials reported similar outcomes with R-DHAP for r/r DLBCL [
         <a href="#rid30">
          30,45
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Retrospective analysis of the CORAL study reported that outcomes varied according to cell-of-origin status and that for patients with GCB-like DLBCL, treatment with R-DHAP was associated with better outcomes than patients treated with R-ICE (three-year progression-free survival [PFS] 100 versus 27 percent) [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3165657005">
         <span class="h4">
          R-ESHAP (rituximab, etoposide, methylprednisolone, cytarabine, cisplatin)
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Administration
         </strong>
         – R-ESHAP refers to
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         375 mg/m
         <sup>
          2
         </sup>
         on day 1,
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          etoposide
         </a>
         40 mg/m
         <sup>
          2
         </sup>
         /day as a one-hour infusion on days 1 to 4,
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         250 to 500 mg/day as a 15-minute infusion on days 1 to 5,
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         25 mg/m
         <sup>
          2
         </sup>
         /day as a continuous infusion from day 1 to 4, and
         <a class="drug drug_general" data-topicid="9314" href="/z/d/drug information/9314.html" rel="external">
          cytarabine
         </a>
         2 g/m
         <sup>
          2
         </sup>
         as a two-hour infusion on day 5, every three or four weeks [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects
         </strong>
         – Hematologic toxicity is universal, with significant rates of neutropenic fever (30 percent) if growth factors are not used. Other AEs (eg, nausea, vomiting, diarrhea, nephrotoxicity, electrolyte disturbances) are generally mild.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Outcomes
         </strong>
         – A retrospective study of 163 patients reported that R-ESHAP for relapsed DLBCL was associated with a 75 to 86 percent ORR and 41 to 50 percent CR, while for primary refractory DLBCL, ORR was 33 percent and CR was 8 percent [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3471388888">
         <span class="h3">
          Response to salvage therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Positron emission tomography (PET) is repeated after completing salvage therapy.
        </p>
        <p class="headingAnchor" id="H2712600041">
         <span class="h4">
          Response criteria
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chemosensitivity (ie, response to salvage therapy) is judged by PET response on the five-point (Deauville) scale  (
         <a class="graphic graphic_table graphicRef108973" href="/z/d/graphic/108973.html" rel="external">
          table 1
         </a>
         ) according to Lugano criteria  (
         <a class="graphic graphic_table graphicRef97479" href="/z/d/graphic/97479.html" rel="external">
          table 5
         </a>
         ).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Complete response
         </strong>
         – PET score 1, 2, or 3 and no residual mediastinal mass.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Partial response
         </strong>
         – PET score 4 or 5 with reduced uptake compared with baseline and no new progressive lesions.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Stable or progressive disease
         </strong>
         – PET score 4 or 5 with no significant change or increased intensity.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3699560335">
         <span class="h4">
          Post-salvage therapy management
         </span>
         <span class="headingEndMark">
          —
         </span>
         Post-salvage therapy management is guided by the PET response  (
         <a class="graphic graphic_algorithm graphicRef142186" href="/z/d/graphic/142186.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="local">
          'Response criteria'
         </a>
         above.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Complete response
         </strong>
         – For patients with CR after salvage therapy, we suggest proceeding to autologous HCT. (See
         <a class="local">
          'Autologous hematopoietic cell transplantation'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         More than one-half of the patients who undergo autologous HCT for r/r DLBCL and achieve CR by PET with salvage therapy are alive five years later [
         <a href="#rid46">
          46-48
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In the phase 3 Parma trial, autologous HCT achieved superior survival compared with salvage therapy alone; however, this trial was conducted prior to routine use of
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         [
         <a href="#rid24">
          24
         </a>
         ]. Further details of the Parma trial are presented above. (See
         <a class="local">
          'Relapse ≥12 months after treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a population-based study, four-year OS was 51 percent with autologous HCT compared with 28 percent four-year OS for the entire population of 239 patients with relapsed DLBCL [
         <a href="#rid49">
          49
         </a>
         ]. A registry study reported 63 percent five-year OS and 48 percent five-year disease-free survival (DFS) after autologous HCT in 470 patients [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Partial response
         </strong>
         – For patients with partial response (PR) after salvage therapy, some experts favor switching to CAR-T cell therapy, while others proceed to autologous HCT.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Those who favor switching to CAR-T cell therapy base that choice on extrapolation from phase 3 trials that demonstrated superior outcomes with CAR-T cell therapy in patients with adverse features (ie, early relapse or primary refractory disease), as discussed above. (See
         <a class="local">
          'Relapse &lt;12 months or primary refractory DLBCL'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Experts who favor proceeding to autologous HCT in patients with a PR after salvage therapy may base that decision on a retrospective review from the CIBMTR (Center for International Blood and Marrow Transplant Research) registry [
         <a href="#rid50">
          50
         </a>
         ]. For patients with PR after salvage therapy for r/r DLBCL, autologous HCT was associated with better two-year OS (69 versus 47 percent; hazard ratio [HR] 1.63 [95% CI 1.14-2.33]) and lower relapse rate (HR 1.49 [95% CI 1.08-2.05]) compared with switching to CAR-T cell therapy. There was no difference in PFS or nonrelapse mortality (NRM). Other CIBMTR analyses reported 41 percent five-year PFS in patients with PR who then underwent autologous HCT [
         <a href="#rid46">
          46,47
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Stable or progressive disease
         </strong>
         – Proceed to management for second or later relapse. (See
         <a class="medical medical_review" href="/z/d/html/132087.html" rel="external">
          "Diffuse large B cell lymphoma (DLBCL): Second or later relapse or patients who are medically unfit", section on 'Medically fit with second or later relapse'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         A systematic review and meta-analysis of 12 studies of autologous HCT, which included 313 patients with relapsed DLBCL, examined the predictive value of PET after salvage therapy [
         <a href="#rid51">
          51
         </a>
         ]. Compared with chemotherapy-sensitive disease, patients with chemotherapy-resistant disease (ie, positive PET after salvage therapy) had shorter PFS (HR 4.3 [95% CI 3.1-6.0]). Other prospective and retrospective studies also reported more favorable outcomes after autologous HCT in patients with chemotherapy-sensitive disease [
         <a href="#rid46">
          46,48,51-54
         </a>
         ]. Patients with PR prior to transplantation have a 30 to 60 percent probability of DFS at three to five years; by comparison, patients with DLBCL that is resistant to salvage chemotherapy have a DFS probability of &lt;10 to 20 percent [
         <a href="#rid7">
          7,55
         </a>
         ]. Other studies also reported the prognostic importance of negative PET after salvage therapy [
         <a href="#rid56">
          56-58
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1237817642">
         <span class="h3">
          Autologous hematopoietic cell transplantation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Autologous HCT consists of myeloablative conditioning chemotherapy followed by infusion of autologous hematopoietic stem/progenitor cells in patients with chemosensitive DLBCL. Results from trials that directly compared autologous HCT versus CAR-T cell therapy are described above. (See
         <a class="local">
          'Relapse &lt;12 months or primary refractory DLBCL'
         </a>
         above.)
        </p>
        <p>
         Transplantation is generally reserved for medically fit patients with relapsed DLBCL who have chemosensitive disease with salvage therapy. There is no age above which the benefits of autologous HCT are clearly outweighed by toxicity [
         <a href="#rid28">
          28
         </a>
         ], but some institutions reserve transplantation for patients ≤75 years.
        </p>
        <p>
         A bone marrow examination should be performed prior to transplantation to exclude involvement of the graft with MDS/neoplasm or AML. Some experts consider evaluation of peripheral blood to exclude features of MDS and AML as an acceptable alternative to bone marrow examination in this setting. Suitability for autologous HCT is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/16354.html" rel="external">
          "Determining eligibility for autologous hematopoietic cell transplantation"
         </a>
         .)
        </p>
        <p>
         Most relapses occur during the first two years after transplantation; NRM surpasses relapse as the main cause of death beginning eight years after transplantation [
         <a href="#rid59">
          59
         </a>
         ]. The most common causes of NRM in the first two years are respiratory failure (31 percent), infection (13 percent), cardiac toxicity (15 percent), and secondary malignancy (15 percent). After two years, secondary malignancies, including MDS, acute leukemia, and solid tumors, are the most common cause of NRM. (See
         <a class="medical medical_review" href="/z/d/html/122403.html" rel="external">
          "Survival, quality of life, and late complications after hematopoietic cell transplantation in adults"
         </a>
         .)
        </p>
        <p>
         Older age (≥50 years), response less than CR, and primary refractory disease were associated with inferior survival in a registry study of patients with DLBCL undergoing autologous HCT [
         <a href="#rid60">
          60
         </a>
         ]. The International Prognostic Index (IPI) identified groups with different OS and PFS among 80 patients undergoing autologous HCT for r/r DLBCL [
         <a href="#rid8">
          8
         </a>
         ]. An analysis of 150 patients from three separate studies also reported that the IPI distinguished groups with different outcomes in this setting [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H399574094">
         <span class="h4">
          Graft source
         </span>
         <span class="headingEndMark">
          —
         </span>
         Peripheral blood stem/progenitor cells (PBSPCs) are generally the preferred graft source for autologous HCT.
        </p>
        <p>
         Compared with bone marrow grafts, PBSPCs yield faster engraftment, less potential for contamination with tumor cells, improved quality of life, lower transplantation-associated costs, and do not require general anesthesia for collection. Sources and collection of autologous grafts are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3537.html" rel="external">
          "Hematopoietic cell transplantation (HCT): Sources of hematopoietic stem/progenitor cells"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3531438648">
         <span class="h4">
          Conditioning regimen
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients who undergo autologous HCT for r/r DLBCL should receive myeloablative conditioning therapy. No myeloablative conditioning regimen has proven superior, and the preferred protocol varies among institutions. The most common conditioning regimens used for r/r DLBCL are:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          BEAM
         </strong>
         <strong>
          (
         </strong>
         <strong>
          carmustine
         </strong>
         <strong>
          [BCNU],
         </strong>
         <strong>
          etoposide
         </strong>
         <strong>
          ,
         </strong>
         <strong>
          cytarabine
         </strong>
         <strong>
          ,
         </strong>
         <strong>
          melphalan
         </strong>
         <strong>
          )
         </strong>
         [
         <a href="#rid61">
          61
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          CBV
         </strong>
         <strong>
          (
         </strong>
         <strong>
          cyclophosphamide
         </strong>
         <strong>
          /BCNU/
         </strong>
         <strong>
          etoposide
         </strong>
         <strong>
          )
         </strong>
         [
         <a href="#rid62">
          62
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Thiotepa
         </strong>
         <strong>
          -based
         </strong>
         <strong>
          (
         </strong>
         <strong>
          thiotepa
         </strong>
         <strong>
          /BCNU or
         </strong>
         <strong>
          thiotepa
         </strong>
         <strong>
          /
         </strong>
         <strong>
          busulfan
         </strong>
         <strong>
          ,
         </strong>
         <strong>
          cyclophosphamide
         </strong>
         <strong>
          )
         </strong>
         [
         <a href="#rid63">
          63
         </a>
         ]
        </p>
        <p>
        </p>
        <p>
         BEAM is generally associated with more gastrointestinal toxicity, while CBV has more pulmonary toxicity [
         <a href="#rid62">
          62,64
         </a>
         ]. Other conditioning regimens have been used less commonly in this setting [
         <a href="#rid62">
          62,65,66
         </a>
         ], but bendamustine-containing conditioning regimens [
         <a href="#rid67">
          67
         </a>
         ] should be avoided because they may impair the collection of T cells, if CAR-T cell therapy is a future consideration.
        </p>
        <p>
         There is no clear benefit to including
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         in the conditioning regimen based on a large registry analysis and retrospective studies [
         <a href="#rid60">
          60,68,69
         </a>
         ].
        </p>
        <p>
         Myeloablative conditioning regimens are discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/3557.html" rel="external">
          "Preparative regimens for hematopoietic cell transplantation", section on 'Myeloablative regimens'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H69089875">
         <span class="h3">
          Post-hematopoietic cell transplantation maintenance therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest
         <strong>
          not
         </strong>
         administering
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         maintenance therapy after autologous HCT because it has no demonstrated benefit [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
         The multicenter CORAL trial that randomly assigned patients to R-ICE versus R-DHAP also included a second randomization to no maintenance therapy versus maintenance
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         375 mg/m
         <sup>
          2
         </sup>
         every two months for a year after autologous HCT [
         <a href="#rid70">
          70
         </a>
         ]. Compared with no maintenance therapy, rituximab maintenance resulted in similar rates of estimated four-year EFS (52 versus 53 percent), PFS (52 versus 56 percent), and OS (61 versus 65 percent), but it was associated with more adverse events after day 100 (mostly infections).
        </p>
        <p class="headingAnchor" id="H1022820075">
         <span class="h1">
          MONITORING
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients should be monitored for relapse and for treatment-related toxicities.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          After chimeric antigen receptor-T cell therapy
         </strong>
         – We generally repeat positron emission tomography (PET)/CT at day 30 and, if positive, repeat it at day 100; after that, we only repeat PET/CT for symptoms.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We monitor immunoglobulin G (IgG) levels and CD4 counts for at least one year. We provide
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         prophylaxis for one year and
         <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">
          trimethoprim-sulfamethoxazole
         </a>
         prophylaxis until CD4 counts are &gt;200/microL.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          After autologous hematopoietic cell transplantation
         </strong>
         – We schedule a follow-up three to six months after transplantation, but there is no consensus for the protocol and schedule of further follow-up, and practices vary among institutions. To limit radiation exposure and because the likelihood of detecting an asymptomatic relapse is small, we limit routine CTs, and we do
         <strong>
          not
         </strong>
         perform regularly scheduled PETs. (See
         <a class="medical medical_review" href="/z/d/html/14228.html" rel="external">
          "Long-term care of the adult hematopoietic cell transplantation survivor", section on 'Autologous HCT'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h1">
          CLINICAL TRIALS
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest participation in a clinical trial for patients with relapsed or refractory DLBCL. Additional information and instructions for referring a patient to an appropriate research center can be obtained from the United States National Institutes of Health (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2F&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlGu03gYcMJXuTK3xOgZRWSzRV8srxVomMWotD038y2Xv&amp;TOPIC_ID=4708" target="_blank">
          www.clinicaltrials.gov
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H2848589081">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/120191.html" rel="external">
          "Society guideline links: Management of diffuse large B cell lymphoma"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H29042151">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/15855.html" rel="external">
          "Patient education: Diffuse large B cell lymphoma (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/15854.html" rel="external">
          "Patient education: Autologous bone marrow transplant (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/117867.html" rel="external">
          "Patient education: Allogeneic bone marrow transplant (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/691.html" rel="external">
          "Patient education: Diffuse large B cell lymphoma in adults (Beyond the Basics)"
         </a>
         and
         <a class="medical medical_patient" href="/z/d/html/686.html" rel="external">
          "Patient education: Hematopoietic cell transplantation (bone marrow transplantation) (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Description
         </strong>
         – Diffuse large B cell lymphoma (DLBCL) that did not respond adequately to initial therapy (primary refractory DLBCL) or recurred after achieving a complete response (CR; relapsed DLBCL) carries an adverse prognosis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – Repeat biopsy is needed to diagnose relapsed DLBCL and for most cases of refractory disease. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pretreatment evaluation
         </strong>
         – Includes (see
         <a class="local">
          'Pretreatment evaluation'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Medical fitness
         </strong>
         – Based on
         <strong>
         </strong>
         performance status  (
         <a class="graphic graphic_table graphicRef72901" href="/z/d/graphic/72901.html" rel="external">
          table 3
         </a>
         ) and comorbid conditions  (
         <a class="graphic graphic_table graphicRef59272" href="/z/d/graphic/59272.html" rel="external">
          table 4
         </a>
         ). (See
         <a class="local">
          'Medical fitness'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Restaging
         </strong>
         – Includes positron emission tomography (PET)/CT. (See
         <a class="local">
          'Restaging'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Prognosis
         </strong>
         – Assessed by the International Prognostic Index  (
         <a class="graphic graphic_table graphicRef70850" href="/z/d/graphic/70850.html" rel="external">
          table 6
         </a>
         ). (See
         <a class="local">
          'Prognosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management
         </strong>
         – The preferred approach for medically fit patients varies with the clinical presentation  (
         <a class="graphic graphic_algorithm graphicRef142186" href="/z/d/graphic/142186.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Refractory or early relapse of DLBCL
         </strong>
         – For refractory disease or early relapse (&lt;12 months after initial therapy), we recommend CD19-directed chimeric antigen receptor (CAR)-T cell therapy using
         <a class="drug drug_general" data-topicid="130728" href="/z/d/drug information/130728.html" rel="external">
          lisocabtagene maraleucel
         </a>
         or
         <a class="drug drug_general" data-topicid="115350" href="/z/d/drug information/115350.html" rel="external">
          axicabtagene ciloleucel
         </a>
         , rather than autologous hematopoietic cell transplantation (HCT) or
         <a class="drug drug_general" data-topicid="114674" href="/z/d/drug information/114674.html" rel="external">
          tisagenlecleucel
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). (See
         <a class="local">
          'Relapse &lt;12 months or primary refractory DLBCL'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         If bridging therapy is required for rapidly progressive disease prior to CAR-T cell therapy, we generally avoid CD19-directed therapy (eg,
         <a class="drug drug_general" data-topicid="129156" href="/z/d/drug information/129156.html" rel="external">
          tafasitamab
         </a>
         , loncastuximab) prior to CD19-directed CAR-T cell therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Late first relapse
         </strong>
         – For first relapse ≥12 months after initial therapy, we suggest autologous HCT (for patients who achieve complete response [CR] or near-CR to salvage chemotherapy) rather than CAR-T cell therapy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Relapse ≥12 months after treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Management of less-fit patients and those with second or later relapse is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/132087.html" rel="external">
          "Diffuse large B cell lymphoma (DLBCL): Second or later relapse or patients who are medically unfit"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Chimeric antigen receptor-T cell therapy
         </strong>
         – CD19-directed CAR-T cell products are generated from the patient's own genetically modified T lymphocytes.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Severe adverse effects include cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, and rare cases of secondary T cell lymphoma. (See
         <a class="medical medical_review" href="/z/d/html/118012.html" rel="external">
          "Cytokine release syndrome (CRS)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/129618.html" rel="external">
          "Immune effector cell-associated neurotoxicity syndrome (ICANS)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Autologous
         </strong>
         <strong>
          hematopoietic cell transplantation
         </strong>
         – Comprises intensive salvage chemotherapy and response assessment, followed by myeloablative transplantation for patients with chemosensitive disease  (
         <a class="graphic graphic_table graphicRef97480" href="/z/d/graphic/97480.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Choice of salvage therapy
         </strong>
         – For relapsed or refractory DLBCL, we suggest intensive salvage therapy rather than lower-intensity salvage therapy to assess chemosensitivity of the tumor (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Salvage regimens'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          No central nervous system involvement
         </strong>
         – For no central nervous system (CNS) involvement or higher-risk features for CNS disease, salvage therapy is selected according to prior therapy, toxicity, comorbidities, institutional preference, and convenience. (See
         <a class="local">
          'No central nervous system involvement'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Central nervous system involvement
         </strong>
         – For CNS involvement or higher risk for CNS involvement, we suggest high-dose cytarabine-based salvage therapy, rather than other intensive salvage regimens (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Central nervous system involvement'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Salvage regimens are described above. (See
         <a class="local">
          'Salvage regimens'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Response to salvage therapy
         </strong>
         – Chemosensitivity is judged by PET response (see
         <a class="local">
          'Response to salvage therapy'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Complete response
         </strong>
         – For CR or near-CR after salvage therapy, we suggest proceeding to autologous HCT (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Partial response
         </strong>
         – For partial response after salvage therapy, some UpToDate experts favor switching to CAR-T cell therapy, while others proceed to autologous HCT. (See
         <a class="local">
          'Post-salvage therapy management'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Stable or progressive disease
         </strong>
         – Treat for second or later relapse. (See
         <a class="medical medical_review" href="/z/d/html/132087.html" rel="external">
          "Diffuse large B cell lymphoma (DLBCL): Second or later relapse or patients who are medically unfit"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Autologous hematopoietic cell transplantation
         </strong>
         – (See
         <a class="local">
          'Autologous hematopoietic cell transplantation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Stem cell source
         </strong>
         – Peripheral blood stem/progenitor cells are generally the preferred graft source in this setting. (See
         <a class="local">
          'Graft source'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Conditioning
         </strong>
         – Myeloablative conditioning therapy is used for autologous HCT. (See
         <a class="local">
          'Conditioning regimen'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          No maintenance therapy
         </strong>
         – We suggest
         <strong>
          no
         </strong>
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         maintenance therapy after autologous HCT (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). (See
         <a class="local">
          'Post-hematopoietic cell transplantation maintenance therapy'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 2010; 116:2040.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Larouche JF, Berger F, Chassagne-Clément C, et al. Lymphoma recurrence 5 years or later following diffuse large B-cell lymphoma: clinical characteristics and outcome. J Clin Oncol 2010; 28:2094.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang Y, Farooq U, Link BK, et al. Late Relapses in Patients With Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy. J Clin Oncol 2019; 37:1819.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weeks JC, Yeap BY, Canellos GP, Shipp MA. Value of follow-up procedures in patients with large-cell lymphoma who achieve a complete remission. J Clin Oncol 1991; 9:1196.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liedtke M, Hamlin PA, Moskowitz CH, Zelenetz AD. Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population. Ann Oncol 2006; 17:909.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cordoba R, Luminari S, Eyre TA. The use of frailty assessments in treating older adults with aggressive lymphomas. Br J Haematol 2021; 194:677.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hamlin PA, Zelenetz AD, Kewalramani T, et al. Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2003; 102:1989.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lerner RE, Thomas W, Defor TE, et al. The International Prognostic Index assessed at relapse predicts outcomes of autologous transplantation for diffuse large-cell non-Hodgkin's lymphoma in second complete or partial remission. Biol Blood Marrow Transplant 2007; 13:486.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010; 28:4184.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blay J, Gomez F, Sebban C, et al. The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group. Blood 1998; 92:3562.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guglielmi C, Gomez F, Philip T, et al. Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial. J Clin Oncol 1998; 16:3264.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vose JM, Weisenburger DD, Loberiza FR, et al. Late relapse in patients with diffuse large B-cell lymphoma. Br J Haematol 2010; 151:354.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cuccuini W, Briere J, Mounier N, et al. MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation. Blood 2012; 119:4619.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. N Engl J Med 2022; 386:640.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kamdar M, Solomon SR, Arnason J, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet 2022; 399:2294.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bishop MR, Dickinson M, Purtill D, et al. Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. N Engl J Med 2022; 386:629.
          </a>
         </li>
         <li class="breakAll">
          FDA Investigating Serious Risk of T-cell Malignancy Following BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies. US Food and Drug Administration, 2023. Available at: https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-investigating-serious-risk-t-cell-malignancy-following-bcma-directed-or-cd19-directed-autologous (Accessed on December 15, 2023).
         </li>
         <li class="breakAll">
          MedWatch: The FDA Safety Information and Adverse Event Reporting Program. US Food and Drug Administration. Available at: https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program (Accessed on December 15, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Westin JR, Oluwole OO, Kersten MJ, et al. Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma. N Engl J Med 2023; 389:148.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elsawy M, Chavez JC, Avivi I, et al. Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma. Blood 2022; 140:2248.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 2020; 396:839.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abramson JS, Solomon SR, Arnason JE, et al. Improved Quality of Life (QOL) with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Compared with Standard of Care (SOC) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 3 Transform Study [#3845]. Blood (ASH Annual Meeting Abstracts) 2021.
          </a>
         </li>
         <li class="breakAll">
          Tisagenlecleucel. United States prescribing information. Revised May 2022. US Food and Drug Administration. https://www.fda.gov/media/107296/download (Accessed on December 22, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333:1540.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bhatt VR, Loberiza FR Jr, Jing H, et al. Mortality patterns among recipients of autologous hematopoietic stem cell transplantation for lymphoma and myeloma in the past three decades. Clin Lymphoma Myeloma Leuk 2015; 15:409.
          </a>
         </li>
         <li class="breakAll">
          https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf (Accessed on September 20, 2018).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tilly H, Gomes da Silva M, Vitolo U, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015; 26 Suppl 5:v116.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oliansky DM, Czuczman M, Fisher RI, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large B cell lymphoma: update of the 2001 evidence-based review. Biol Blood Marrow Transplant 2011; 17:20.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jacobson CA. CD19 Chimeric Antigen Receptor Therapy for Refractory Aggressive B-Cell Lymphoma. J Clin Oncol 2019; 37:328.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crump M, Kuruvilla J, Couban S, et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. J Clin Oncol 2014; 32:3490.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Corazzelli G, Capobianco G, Arcamone M, et al. Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma. Cancer Chemother Pharmacol 2009; 64:907.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martín A, Conde E, Arnan M, et al. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study. Haematologica 2008; 93:1829.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crump M, Baetz T, Couban S, et al. Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). Cancer 2004; 101:1835.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gopal AK, Press OW, Shustov AR, et al. Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology Consortium. Leuk Lymphoma 2010; 51:1523.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thieblemont C, Briere J, Mounier N, et al. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study. J Clin Oncol 2011; 29:4079.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kewalramani T, Zelenetz AD, Nimer SD, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2004; 103:3684.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simpson L, Ansell SM, Colgan JP, et al. Effectiveness of second line salvage chemotherapy with ifosfamide, carboplatin, and etoposide in patients with relapsed diffuse large B-cell lymphoma not responding to cis-platinum, cytosine arabinoside, and dexamethasone. Leuk Lymphoma 2007; 48:1332.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           El Gnaoui T, Dupuis J, Belhadj K, et al. Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. Ann Oncol 2007; 18:1363.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mounier N, El Gnaoui T, Tilly H, et al. Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial. Haematologica 2013; 98:1726.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           López A, Gutiérrez A, Palacios A, et al. GEMOX-R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell lymphoma: a phase II study. Eur J Haematol 2008; 80:127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cazelles C, Belhadj K, Vellemans H, et al. Rituximab plus gemcitabine and oxaliplatin (R-GemOx) in refractory/relapsed diffuse large B-cell lymphoma: a real-life study in patients ineligible for autologous stem-cell transplantation. Leuk Lymphoma 2021; 62:2161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tessoulin B, Thomare P, Delande E, et al. Carboplatin instead of cisplatin in combination with dexamethasone, high-dose cytarabine with or without rituximab (DHAC+/-R) is an effective treatment with low toxicity in Hodgkin's and non-Hodgkin's lymphomas. Ann Hematol 2017; 96:943.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lacout C, Orvain C, Seegers V, et al. R-DHA-oxaliplatin (R-DHAOx) versus R-DHA-cisplatin (R-DHAP) regimen in B-cell lymphoma treatment: A eight-year trajectory study. Eur J Haematol 2020; 105:223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lignon J, Sibon D, Madelaine I, et al. Rituximab, dexamethasone, cytarabine, and oxaliplatin (R-DHAX) is an effective and safe salvage regimen in relapsed/refractory B-cell non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk 2010; 10:262.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Imhoff GW, McMillan A, Matasar MJ, et al. Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study. J Clin Oncol 2016; :JCO2016690198.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sauter CS, Matasar MJ, Meikle J, et al. Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma. Blood 2015; 125:2579.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shah NN, Ahn KW, Litovich C, et al. Is autologous transplant in relapsed DLBCL patients achieving only a PET+ PR appropriate in the CAR T-cell era? Blood 2021; 137:1416.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Armand P, Welch S, Kim HT, et al. Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era. Br J Haematol 2013; 160:608.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Farooq U, Maurer MJ, Thompson CA, et al. Clinical heterogeneity of diffuse large B cell lymphoma following failure of front-line immunochemotherapy. Br J Haematol 2017; 179:50.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mounier N, Canals C, Gisselbrecht C, et al. High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry. Biol Blood Marrow Transplant 2012; 18:788.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Terasawa T, Dahabreh IJ, Nihashi T. Fluorine-18-fluorodeoxyglucose positron emission tomography in response assessment before high-dose chemotherapy for lymphoma: a systematic review and meta-analysis. Oncologist 2010; 15:750.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roland V, Bodet-Milin C, Moreau A, et al. Impact of high-dose chemotherapy followed by auto-SCT for positive interim [18F] FDG-PET diffuse large B-cell lymphoma patients. Bone Marrow Transplant 2011; 46:393.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Filmont JE, Gisselbrecht C, Cuenca X, et al. The impact of pre- and post-transplantation positron emission tomography using 18-fluorodeoxyglucose on poor-prognosis lymphoma patients undergoing autologous stem cell transplantation. Cancer 2007; 110:1361.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dickinson M, Hoyt R, Roberts AW, et al. Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pre-transplant FDG-PET scan following salvage chemotherapy. Br J Haematol 2010; 150:39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vose JM, Zhang MJ, Rowlings PA, et al. Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 2001; 19:406.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spaepen K, Stroobants S, Dupont P, et al. Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood 2003; 102:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Derenzini E, Musuraca G, Fanti S, et al. Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma. Cancer 2008; 113:2496.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoppe BS, Moskowitz CH, Zhang Z, et al. The role of FDG-PET imaging and involved field radiotherapy in relapsed or refractory diffuse large B-cell lymphoma. Bone Marrow Transplant 2009; 43:941.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hill BT, Rybicki L, Bolwell BJ, et al. The non-relapse mortality rate for patients with diffuse large B-cell lymphoma is greater than relapse mortality 8 years after autologous stem cell transplantation and is significantly higher than mortality rates of population controls. Br J Haematol 2011; 152:561.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jagadeesh D, Majhail NS, He Y, et al. Outcomes of rituximab-BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation. Cancer 2020; 126:2279.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaspard MH, Maraninchi D, Stoppa AM, et al. Intensive chemotherapy with high doses of BCNU, etoposide, cytosine arabinoside, and melphalan (BEAM) followed by autologous bone marrow transplantation: toxicity and antitumor activity in 26 patients with poor-risk malignancies. Cancer Chemother Pharmacol 1988; 22:256.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen YB, Lane AA, Logan BR, et al. Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 2015; 21:1046.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cote GM, Hochberg EP, Muzikansky A, et al. Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2012; 18:76.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caballero MD, Rubio V, Rifon J, et al. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors. Bone Marrow Transplant 1997; 20:451.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murata M, Nishida T, Haneda M, et al. A new preconditioning regimen with melphalan, busulphan and total body irradiation followed by low-dose immunosuppressant in allogeneic haemopoietic stem cell transplantation. Br J Haematol 1999; 105:799.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bacigalupo A, Vitale V, Corvò R, et al. The combined effect of total body irradiation (TBI) and cyclosporin A (CyA) on the risk of relapse in patients with acute myeloid leukaemia undergoing allogeneic bone marrow transplantation. Br J Haematol 2000; 108:99.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Visani G, Malerba L, Stefani PM, et al. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. Blood 2011; 118:3419.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vose JM, Carter S, Burns LJ, et al. Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 trial. J Clin Oncol 2013; 31:1662.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flohr T, Hess G, Kolbe K, et al. Rituximab in vivo purging is safe and effective in combination with CD34-positive selected autologous stem cell transplantation for salvage therapy in B-NHL. Bone Marrow Transplant 2002; 29:769.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gisselbrecht C, Schmitz N, Mounier N, et al. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma. J Clin Oncol 2012; 30:4462.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 4708 Version 90.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20548096" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20308668" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Lymphoma recurrence 5 years or later following diffuse large B-cell lymphoma: clinical characteristics and outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31170029" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Late Relapses in Patients With Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1710656" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Value of follow-up procedures in patients with large-cell lymphoma who achieve a complete remission.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16672295" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33713435" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : The use of frailty assessments in treating older adults with aggressive lymphomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12676776" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17382255" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : The International Prognostic Index assessed at relapse predicts outcomes of autologous transplantation for diffuse large-cell non-Hodgkin's lymphoma in second complete or partial remission.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20660832" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9808548" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9779700" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20880118" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Late relapse in patients with diffuse large B-cell lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22408263" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34891224" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35717989" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34904798" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34904798" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34904798" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37272527" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35839452" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32888407" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Improved Quality of Life (QOL) with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Compared with Standard of Care (SOC) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 3 Transform Study [#3845]
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Improved Quality of Life (QOL) with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Compared with Standard of Care (SOC) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 3 Transform Study [#3845]
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7477169" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25816932" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Mortality patterns among recipients of autologous hematopoietic stem cell transplantation for lymphoma and myeloma in the past three decades.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25816932" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Mortality patterns among recipients of autologous hematopoietic stem cell transplantation for lymphoma and myeloma in the past three decades.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26314773" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20656046" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large B cell lymphoma: update of the 2001 evidence-based review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30557517" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : CD19 Chimeric Antigen Receptor Therapy for Refractory Aggressive B-Cell Lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25267740" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19219604" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18945747" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15386331" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20578815" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology Consortium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21947824" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14739217" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17613762" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Effectiveness of second line salvage chemotherapy with ifosfamide, carboplatin, and etoposide in patients with relapsed diffuse large B-cell lymphoma not responding to cis-platinum, cytosine arabinoside, and dexamethasone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17496309" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23753028" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18005385" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : GEMOX-R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell lymphoma: a phase II study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33764240" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Rituximab plus gemcitabine and oxaliplatin (R-GemOx) in refractory/relapsed diffuse large B-cell lymphoma: a real-life study in patients ineligible for autologous stem-cell transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28374163" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Carboplatin instead of cisplatin in combination with dexamethasone, high-dose cytarabine with or without rituximab (DHAC+/-R) is an effective treatment with low toxicity in Hodgkin's and non-Hodgkin's lymphomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32302426" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : R-DHA-oxaliplatin (R-DHAOx) versus R-DHA-cisplatin (R-DHAP) regimen in B-cell lymphoma treatment: A eight-year trajectory study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20709662" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Rituximab, dexamethasone, cytarabine, and oxaliplatin (R-DHAX) is an effective and safe salvage regimen in relapsed/refractory B-cell non-Hodgkin lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28029326" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25758829" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33120429" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Is autologous transplant in relapsed DLBCL patients achieving only a PET+ PR appropriate in the CAR T-cell era?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23278720" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28653407" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Clinical heterogeneity of diffuse large B cell lymphoma following failure of front-line immunochemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22005647" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20587551" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Fluorine-18-fluorodeoxyglucose positron emission tomography in response assessment before high-dose chemotherapy for lymphoma: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20577223" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Impact of high-dose chemotherapy followed by auto-SCT for positive interim [18F] FDG-PET diffuse large B-cell lymphoma patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17623832" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : The impact of pre- and post-transplantation positron emission tomography using 18-fluorodeoxyglucose on poor-prognosis lymphoma patients undergoing autologous stem cell transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20507301" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pre-transplant FDG-PET scan following salvage chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11208832" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12609836" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18833583" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19139730" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : The role of FDG-PET imaging and involved field radiotherapy in relapsed or refractory diffuse large B-cell lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21223255" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : The non-relapse mortality rate for patients with diffuse large B-cell lymphoma is greater than relapse mortality 8 years after autologous stem cell transplantation and is significantly higher than mortality rates of population controls.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32049359" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Outcomes of rituximab-BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3044633" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Intensive chemotherapy with high doses of BCNU, etoposide, cytosine arabinoside, and melphalan (BEAM) followed by autologous bone marrow transplantation: toxicity and antitumor activity in 26 patients with poor-risk malignancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25687795" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21749848" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9313877" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10354150" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : A new preconditioning regimen with melphalan, busulphan and total body irradiation followed by low-dose immunosuppressant in allogeneic haemopoietic stem cell transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10651732" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : The combined effect of total body irradiation (TBI) and cyclosporin A (CyA) on the risk of relapse in patients with acute myeloid leukaemia undergoing allogeneic bone marrow transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21816830" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23478060" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12040475" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Rituximab in vivo purging is safe and effective in combination with CD34-positive selected autologous stem cell transplantation for salvage therapy in B-NHL.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23091101" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
